IMMUNOLOGICAL IMBALANCE IN BREAST CANCER AND LUNG CANCER IN POSTMENOPAUSAL WOMEN

Previous studies reported some associations between class A antibodies specific for benzo[a]pyrene (IgA-Bp), estradiol (IgA-Es) and progesterone (IgA-Pg) and breast cancer (BC) in women like as with lung cancer (LC) in men. It was suggested that IgA-Bp and IgA-Es may stimulate tumor initiation and promotion, whereas IgA-Pg may inhibit the in vivo human carcinogenesis.
The purpose of this study was to identify the suggested associations of such immunological imbalance with BC and LC in postmenopausal women.
The serum A-class antibodies specific to benzo[a]pyrene, estradiol and progesterone (IgA-Bp, IgA-Es, IgA- Pg) were studied in 335 healthy women, 824 breast cancer (BC) patients and 127 cases of lung cancer (LC) by means of non-competitive solid phase immunoassay. The following results were obtained: Increased ratio of IgA-Bp and IgA-Es amounts exceeding the IgA-Pg levels was associated with a higher risk of breast cancer (OR = 2.8 and 2.4 respectively, p < 0.0001), and higher risk of LC (OR = 2.9 and 2.8, respectively, p < 0.0001). Conversely, the OR values decreased to 0.3-0.4 for BC and LC if IgA-Pg levels were higher than IgA-Bp and IgA-Es levels (p < 0.0001). These findings confirm the hypothesis that IgA-Bp and IgA-Es are capable to stimulate, and IgA-Pg, to inhibit the BC and LC occurrence n postmenopausal women. The balance between IgA-Bp and IgA-Es, on the one hand, and IgA-Pg, on the other hand, is much more important than individual contents of these antibodies.
In conclusion, the phenomenon of “immunological interference” is revealed, i.e., the mutual enhancement of IgA-Bp and IgA-Es effects, thus, probably, stimulating the initial and subsequent events of carcinogenesis initiation and promotion, with a weak anticancer effect of IgA-Pg, and by weakening the mutual procarcinogenic effects of IgA-Bp and IgA-Es by the marked effect of IgA-Pg.

1. Богуш Т.А., Дудко Е.А., Беме А.А., Богуш Е.А., Ким А.И., Полоцкий Б.Е., Тюляндин С.А., Давыдов М.И. Эстрогеновые рецепторы, антиэстрогены и немелкоклеточный рак легкого // Биохимия, 2010. Т. 75, № 12. С. 1633-1641. [Bogush T.A., Dudko E.A., Beme A.A., Bogush E.A., Kim A.I., Polotsky B.E., Tjuljandin S.A., Davydov M.I. Estrogen receptors, antiestrogens, and non-small cell lung cancer. Biokhimiya = Biochemistry, 2010, Vol. 75, no. 12, pp. 1633-1641. (In Russ.)]

2. Глушков А.Н., Поленок Е.Г., Аносова Т.П., Савченко Я.А., Баканова М.Л., Минина В.И., Мун С.А., Ларин С.А., Костянко М.В. Сывороточные антитела к бензо[a]пирену и хромосомные аберрации в лимфоцитах периферической крови у рабочих углеперерабатывающего предприятия // Российский иммунологический журнал, 2011. Т. 5 (14), № 1. С. 39-44. [Glushkov A.N., Polenok E.G., Anosova T.P., Savchenko Ya.A., Bakanova M.L., Minina V.I., Mun S.A., Larin S.A., Kostyanko M.V. Serum antibodies to benzo[a]pyrene and chromosomal aberrations in lymphocytes peripheral blood at the workers of coal processing enterprise. Rossiyskiy immunologicheskiy zhurnal = Russian Journal of Immunology, 2011, Vol. 5 (14), no. 1, pp. 39-44. (In Russ.)]

3. Глушков А.Н., Поленок Е.Г., Костянко М.В., Антонов А.В., Вержбицкая Н.Е., Вафин И.А., Рагожина С.Е. Ассоциации сывороточных антител к эстрадиолу с рецепторами эстрогенов в опухоли у больных раком молочной железы // Российский иммунологический журнал, 2016. T. 10 (19), № 2. С. 166- 173. [Glushkov A.N., Polenok E.G., Kostyanko M.V., Antonov A.V., Verzhbitskaya N.E., Vafin I.A., Ragozhina S.E. Associations of the serum antibodies to estradiol and the tumor estrogen receptors at the breast cancer patients. Rossiyskiy immunologicheskiy zhurnal = Russian Journal of Immunology, 2016, Vol. 10 (19), no. 2, pp. 166-173. (In Russ.)]

4. Глушков А.Н., Поленок Е.Г., Костянко М.В., Антонов А.В., Вержбицкая Н.Е., Вафин И.А., Рагожина С.Е. Антитела и анти-антитела к стероидным гормонам и риск рака молочной железы // Медицинская иммунология, 2017. Т. 19, № 5. С. 577-584. [Glushkov A.N., Polenok E.G., Kostyanko M.V., Antonov A.V., Verzhbitskaya N.E., Vafin I.A., Ragozhina S.E. Antibodies and anti-antibodies to steroid hormones, and breast cancer risk. Meditsinskaya immunologiya = Medical Immunology (Russia), 2017, Vol. 19, no. 5, pp. 577-584. (In Russ.)] doi:10.15789/1563-0625-2017-5-577-584.

5. Глушков А.Н., Поленок Е.Г., Костянко М.В., Титов В.А., Вафин И.А., Рагожина С.Е. Взаимное влияние антител к бензо[a]пирену, эстрадиолу и прогестерону на риски возникновения рака легкого // Российский иммунологический журнал, 2015. Т. 9 (18), № 3. С. 343-349. [Glushkov A.N., Polenok E.G., Kostyanko M.V., Titov V.A., Vafin I.A., Ragozhina S.E. Mutual effects of antibodies to benzo[a]pyrene, estradiol and progesterone on the lung cancer risks. Rossiyskiy immunologicheskiy zhurnal = Russian Journal of Immunology, 2015, Vol. 9 (18), no. 3, pp. 343-349. (In Russ.)]

6. Глушков А.Н., Поленок Е.Г., Магарилл Ю.А., Аносова Т.П., Антонов А.В., Вержбицкая Н.Е. Антитела к бензо[а]пирену, эстрадиолу и прогестерону у больных раком молочной железы в постменопаузе // Сибирский онкологический журнал, 2016. Т. 15, № 6. С. 28-34. [Glushkov A.N., Polenok E.G., Magarill Yu.A., Anosova T.P., Antonov A.V., Verzhbitskaya N.E. Antibodies to benzo[a]pyrene, estradiol and progesterone in the postmenopausal breast cancer women. Sibirskiy onkologicheskiy zhurnal = Siberian Journal of Oncology, 2016, Vol. 15, no. 6, pp. 28-34. (In Russ.)]

7. Давыдов М.И., Богуш Т.А., Полоцкий Б.Е., Тюляндин С.А. Эстрогеновые рецепторы β – новая мишень в терапии немелкоклеточного рака легкого // Вестник РАМН, 2012. Т. 67, № 2. С. 16-22. [Davidov M.I., Bogush T.A., Polotsky B.E., Тyulyandin S.A. Estrogen receptors β – new target in cellular lung cancer treatment. Vestnik RAMN = Annals of the Russian Academy of Medical Sciences, 2012, Vol. 67, no. 2, pp. 16-22. (In Russ.)]

8. Bouchardy C., Benhamou S., Schaffar R., Verkooijen H.M., Fioretta G., Schubert H., Vinh-Hung V.,

9. Soria J.C., Vlastos G., Rapiti E. Lung cancer mortality risk among breast cancer patients treated with anti-estrogens. Cancer, 2011, Vol. 117, no. 6, pp. 1288-1295.

10. Caldwell B.V., Tillson S.A., Esber H., Thorneycroft I.H. Survival of tumors after immunization against estrogens. Nature, 1971, Vol. 231, no. 14, pp. 118-119.

11. Cavalieri E.L., Rogan E.G., Zahid M. Critical depurinating DNA adducts: Estrogen adducts in the etiology and prevention of cancer and dopamine adducts in the etiology and prevention of Parkinson’s disease. Int. J. Cancer, 2017, Vol. 141, no. 6, pp. 1078-1090.

12. Černohorská H., Klimešová S., Lepša L., Jinoch P., Milcová A., Schmuczerová J., Topinka J., Lábaj J. Influence of immunization with non-genotoxic PAH-KLH conjugates on the resistance of organisms exposed to benzo[a] pyrene. Mut. Res., 2012, Vol. 742, no. 1-2, pp. 2-10.

13. de Buck S.S., Augustijns P., Muller C.P. Specific antibody modulates absorptive transport and metabolic activation of benzo[a]pyrene across Caco-2 monolayers. J. Pharmacol. Experim. Therap., 2005, Vol. 313, no. 2, pp. 640-646.

14. de Buck S.S., Schellenberger M.T., Ensch C., Muller C.P. Effects of antibodies induced by a conjugate vaccine on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone absorptive transport, metabolism, and proliferation of human lung cells. Int. J. Cancer, 2010, Vol. 127, no. 3, pp. 513-520.

15. Glushkov A.N., Polenok E.G., Ustinov V.A. Immunomodulation of human carcinogenesis by the blood serum antibodies to environmental carcinogens and endogenous steroids. Open Immunol. J., 2016, Vol. 6, no. 3, pp. 67-72.

16. Grova N., Prodhomme E.J., Schellenberger M.T., Farinelle S., Muller C.P. Modulation of carcinogen bioavailability by immunisation with benzo[a]pyrene – conjugate vaccines. Vaccine, 2009, Vol. 27, no. 31, pp. 4142-4151.

17. Hajian-Tilaki K. Receiver operating characteristic (ROC) curve analysis for medical diagnostic test evaluation. Caspian J. Intern. Med., 2013, Vol. 4, no. 2, pp. 627-635.

18. Hillier S.G., Groom G.V., Boyns A.R., Cameron E.H. Effects of active immunisation against steroids upon circulating hormone concentrations. J. Steroid Biochem., 1975, Vol. 6, no. 3-4, pp. 529-535.

19. LaCroix A.Z., Powles T., Osborne C.K., Wolter K., Thompson J.R., Thompson D.D., Allred D.C., Armstrong R., Cummings S.R., Eastell R., Ensrud K.E., Goss P., Lee A., Neven P., Reid D.M., Curto M., Vukicevic S. Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women. J. Natl. Cancer Inst., 2010, Vol. 102, no. 22, pp. 1706-1715.

20. Mohammed H., Russell I.A., Stark R., Rueda O.M., Hickey T.E., Tarulli G.A., Serandour A.A., Birrell S.N., Bruna A., Saadi A., Menon S., Hadfield J., Pugh M., Raj G.V., Brown G.D., D’Santos C., Robinson J.L., Silva G., Launchbury R., Perou C.M., Stingl J., Caldas C., Tilley W.D., Carroll J.S. Progesterone receptor modulates ERα action in breast cancer. Nature, 2015, Vol. 523, no. 7560, pp. 313-317.

21. Rastogi P. Chemoprevention in postmenopausal women. Menopause, 2008, Vol. 15, no. 4, pp. 810-815.

22. Rundle A., Tang D., Hibshoosh H., Estabrook A., Schnabel F., Cao W., Grumet S., Perera F.P. The relationship between genetic damage from polycyclic aromatic hydrocarbons in breast tissue and breast cancer. Carcinogenesis, 2000, Vol. 21, no. 7, pp. 1281-1289.

23. Schwartz U., Dyrenfurth I., Khalaf S., Vande Wiele R.L., Ferin M. A comparison of the effects of active immunization of female rhesus monkeys to estradiol-17 or progesterone-20-protein conjugates. J. Steroid Biochem., 1975, Vol. 6, no. 3-4, pp. 541-545.

24. Sestak I. Preventative therapies for healthy women at high risk of breast cancer. Cancer Manag. Res., 2014, Vol. 6, pp. 423-430.

25. Siegel R.L., Miller K.D., Jemal A. Cancer Statistics, 2017. CA Cancer J. Clin., 2017, Vol. 67, no. 1, pp. 7-30.

26. Sundaram K., Tsong Y.Y., Hood W., Brinson A. Effect of immunization with estrone-protein conjugate in rhesus monkeys. Endocrinology, 1973, Vol. 93, no. 4, pp. 843-847.

27. Ustinov V.A., Matveeva V.A., Kostyanko M.V., Glushkov A.N., Antibodies against benzo[a]pyrene in immunized mouse and in lung cancer patients. Exp. Oncol., 2013, Vol. 35, no. 3, pp. 207-210.

28. Vogel V.G. Role of hormones in cancer prevention. Am. Soc. Clin. Oncol. Educ. Book, 2014, pp. 34-40.